Remdesivir, an antiviral drug with the potential to treat COVID, has been largely ignored since its "introduction" to the world at the beginning of COVID. It just didn't seem to work very well. But data from a Phase 3 trial by Gilead was a surprise. The drug, when given to COVID patients in a non-hospital setting, did a very good job of keeping them out of the hospital. Here's a summary of the clinical data.
It's looking like winter will arrive with rising numbers of cases in the U.S. and Europe. Hospitals are again beginning to fill up. But there's some evidence that the hard-won lessons in treating COVID-19 are beginning to improve outcomes.
There are about 2,000 drugs and vaccines (mostly the former) now in clinical trials. ACSH advisor Dr. Henry Miller argues that to get COVID-19 under control we will need therapeutics no matter how effective vaccines are. Here's why.
Another clinical trial of remdesivir – this time with hospitalized patients having moderate COVID-19 – yielded disappointing and strange results. The first randomized trial showed a modest benefit in patients with severe COVID, so theoretically the drug should have worked better in patients who weren't as sick. But, it didn't.
We have made amazing progress in the treatment of COVID-19. Two therapies – steroids and remdesivir – have already been shown to help. Those who benefit from these treatments owe thanks to patients who volunteered to participate in controlled clinical trials, and the physicians and pharmaceutical companies that lead them.
As an anti-coronavirus therapy, Remdesivir has been rather disappointing. That's primarily because the drug is given intravenously to those who are already very ill with COVID-19. But what would happen if the drug could be delivered directly to the lungs, to prevent severe disease? Gilead is giving it a shot. Here are some of the pros and cons of that approach.
Somewhere along the way, our achievable goal of "flattening the curve" for COVID-19 has mutated into "finding a cure," which is perhaps an impossible one. Public health and economic policy must be based on reality, not starry-eyed wish-making. Otherwise, people's lives and livelihoods are in grave danger.
Drugs that don't work when taken orally are the bane of drug discovery chemists. Now it's the bane of the world. But there are techniques that can convert orally inactive drugs, like remdesivir, into pills. Here's how they work.
Remdesivir arrived with great hope and even greater expectations. Would this drug finally awake us from the 2-plus-month long nightmare that has the U.S. tossing and turning in its sleep? As things stand now that answer is no. Here's why.
Remdesivir appears to be our first promising treatment for COVID-19. It is certainly neither a cure nor a preventative. But it seems to reduce the length of hospital stays, and thus, increases the health systems’ capacity by about a third. So if you were in charge of selling this drug, what price would you set?
After months of speculation, the results of the first placebo-controlled trial of remdesivir are out. The drug does help people with COVID-19 disease, but it's nothing to get excited about. Here's why.
The first data from the SIMPLE trial of remdesivir has been released by Gilead. Even though this is the first complete trial of the drug, it doesn't answer many questions. That's because there was no control group – something that would have been unethical for the trial participants since they had severe disease. We're just getting started.